×
About 10,320 results

ALLMedicine™ Idiopathic Pulmonary Fibrosis Center

Research & Reviews  3,415 results

Inflammatory bowel disease and risk of idiopathic pulmonary fibrosis: A protocol for sy...
https://doi.org/10.1371/journal.pone.0270297
PloS One; Wang J, Kou F et. al.

Jun 25th, 2022 - Inflammatory bowel disease is a relapsing chronic gastrointestinal inflammatory disease. Idiopathic pulmonary fibrosis is a rare but serious extraintestinal pulmonary manifestation of inflammatory bowel disease. However, the relationship between t...

Revealing the pathogenic and ageing-related mechanisms of the enigmatic idiopathic pulm...
https://doi.org/10.1097/MCP.0000000000000876
Current Opinion in Pulmonary Medicine; Spagnolo P, Semenzato U

Jun 25th, 2022 - Growing evidence suggests that ageing-associated alterations occur in both idiopathic pulmonary fibrosis (IPF) and chronic obstructive pulmonary disease (COPD). Here, we review the most recent literature on dysregulated ageing pathways in IPF and ...

An Expanded Access Program in Belgium to Provide Nintedanib to People With Lung Diseases Called Non-IPF ILDs Who Have no Alternative Treatment Options
https://clinicaltrials.gov/ct2/show/NCT04739150

Jun 24th, 2022 - This Expanded Access Program in Belgium is open to people with different lung diseases. This program provides a medicine called nintedanib to people who have no alternative treatment options. They can participate if they have a type of lung diseas...

Efficacy and Safety Study of Orvepitant for Chronic Cough in Patients With Idiopathic Pulmonary Fibrosis
https://clinicaltrials.gov/ct2/show/NCT05185089

Jun 24th, 2022 - The study will be a multi-center, double-blind, randomised, placebo-controlled 2-period cross-over study in subjects with chronic cough due to idiopathic pulmonary fibrosis (IPF). Subjects will participate in one of two cohorts (Cohort 1 and Cohor...

Characterization of Apolipoprotein A-I Pathways in Idiopathic Pulmonary Fibrosis
https://clinicaltrials.gov/ct2/show/NCT02315586

Jun 24th, 2022 - Idiopathic Pulmonary Fibrosis (IPF) is a chronic progressive disease that occurs primarily in older individuals, 55 to 75 years of age, with a median survival of approximately 3 years from time of diagnosis. At present, there are no effective trea...

see more →

Guidelines  6 results

Idiopathic Pulmonary Fibrosis (an Update) and Progressive Pulmonary Fibrosis in Adults:...
https://doi.org/10.1164/rccm.202202-0399ST
American Journal of Respiratory and Critical Care Medicine; Raghu G, Remy-Jardin M et. al.

Apr 30th, 2022 - Background: This American Thoracic Society, European Respiratory Society, Japanese Respiratory Society, and Asociación Latinoamericana de Tórax guideline updates prior idiopathic pulmonary fibrosis (IPF) guidelines and addresses the progression of...

S2K Guideline for Diagnosis of Idiopathic Pulmonary Fibrosis.
https://doi.org/10.1159/000512315
Respiration; International Review of Thoracic Diseases; Behr J, Günther A et. al.

Jan 25th, 2021 - Idiopathic pulmonary fibrosis (IPF) is a severe and often fatal disease. Diagnosis of IPF requires considerable expertise and experience. Since the publication of the international IPF guideline in the year 2011 and the update 2018 several studies...

Guidelines of the Polish Respiratory Society for diagnosis and treatment of idiopathic ...
https://doi.org/10.5603/ARM.2020.0081
Advances in Respiratory Medicine; Piotrowski WJ, Bestry I et. al.

Mar 11th, 2020 - This document presents the guidelines of the Polish Respiratory Society (PTChP, Polskie Towarzystwo Chorób Płuc) for diagnosis and treatment of idiopathic pulmonary fibrosis (IPF), developed by agroup of Polish experts. The recommendations were de...

Diagnosis of Idiopathic Pulmonary Fibrosis. An Official ATS/ERS/JRS/ALAT Clinical Pract...
https://doi.org/10.1164/rccm.201807-1255ST
American Journal of Respiratory and Critical Care Medicine; Raghu G, Remy-Jardin M et. al.

Sep 1st, 2018 - This document provides clinical recommendations for the diagnosis of idiopathic pulmonary fibrosis (IPF). It represents a collaborative effort between the American Thoracic Society, European Respiratory Society, Japanese Respiratory Society, and L...

An Official ATS/ERS/JRS/ALAT Clinical Practice Guideline: Treatment of Idiopathic Pulmo...
https://doi.org/10.1164/rccm.201506-1063ST
American Journal of Respiratory and Critical Care Medicine; Raghu G, Rochwerg B et. al.

Jul 16th, 2015 - This document updates the American Thoracic Society/European Respiratory Society/Japanese Respiratory Society/Latin American Thoracic Association guideline on idiopathic pulmonary fibrosis treatment. Systematic reviews and, when appropriate, meta-...

see more →

Drugs  23 results see all →

Clinicaltrials.gov  396 results

An Expanded Access Program in Belgium to Provide Nintedanib to People With Lung Diseases Called Non-IPF ILDs Who Have no Alternative Treatment Options
https://clinicaltrials.gov/ct2/show/NCT04739150

Jun 24th, 2022 - This Expanded Access Program in Belgium is open to people with different lung diseases. This program provides a medicine called nintedanib to people who have no alternative treatment options. They can participate if they have a type of lung diseas...

Efficacy and Safety Study of Orvepitant for Chronic Cough in Patients With Idiopathic Pulmonary Fibrosis
https://clinicaltrials.gov/ct2/show/NCT05185089

Jun 24th, 2022 - The study will be a multi-center, double-blind, randomised, placebo-controlled 2-period cross-over study in subjects with chronic cough due to idiopathic pulmonary fibrosis (IPF). Subjects will participate in one of two cohorts (Cohort 1 and Cohor...

Characterization of Apolipoprotein A-I Pathways in Idiopathic Pulmonary Fibrosis
https://clinicaltrials.gov/ct2/show/NCT02315586

Jun 24th, 2022 - Idiopathic Pulmonary Fibrosis (IPF) is a chronic progressive disease that occurs primarily in older individuals, 55 to 75 years of age, with a median survival of approximately 3 years from time of diagnosis. At present, there are no effective trea...

INREAL - Nintedanib for Changes in Dyspnea and Cough in Patients Suffering From Chronic Fibrosing Interstitial Lung Disease (ILD) With a Progressive Phenotype in Everyday Clinical Practice: a Real-...
https://clinicaltrials.gov/ct2/show/NCT04702893

Jun 24th, 2022 - The primary objective of this observational study is to investigate the correlation between changes from baseline at 52 weeks in forced vital capacity (FVC) and changes from baseline at 52 weeks in dyspnea score points or cough score points as mea...

Lung Disease Associated With Rheumatoid Arthritis
https://clinicaltrials.gov/ct2/show/NCT00001876

Jun 24th, 2022 - Pulmonary fibrosis is an extra-articular manifestation of rheumatoid arthritis whose etiology remains uncertain. Although the clinical course of many individuals with this disorder can mimic that observed in patients with idiopathic pulmonary fibr...

see more →

News  283 results

Fast Five Quiz: Idiopathic Pulmonary Fibrosis Imaging
https://reference.medscape.com/viewarticle/925458

Jun 21st, 2022 - Idiopathic pulmonary fibrosis (IPF) is a rare form of chronic, progressive fibrosing interstitial pneumonia of unknown etiology. Global incidence and prevalence of IPF are between 0.09 and 1.30 per 10,000 people, according to Mei and colleagues. I...

Fast Five Quiz: Progressive Fibrosing Interstitial Lung Disease Presentation and Diagnosis
https://reference.medscape.com/viewarticle/946214

Jun 16th, 2022 - Progressive fibrosing interstitial lung diseases (PF-ILD) are a heterogeneous group of interstitial lung diseases clinically characterized by accelerated respiratory failure, frequent disease exacerbation, decreased quality of life, and earlier mo...

Fast Five Quiz: Progressive Fibrosing Interstitial Lung Disease Presentation and Diagnosis
https://www.medscape.com/viewarticle/946214

Jun 16th, 2022 - Progressive fibrosing interstitial lung diseases (PF-ILD) are a heterogeneous group of interstitial lung diseases clinically characterized by accelerated respiratory failure, frequent disease exacerbation, decreased quality of life, and earlier mo...

Living and leading with lung disease
https://www.mdedge.com/chestphysician/article/255339/society-news/living-and-leading-lung-disease

Jun 13th, 2022 - Receiving a chronic disease diagnosis can be paralyzing, with a wide range of associated emotions. A patient’s family, physicians, and other health care professionals can provide a source of support, but, often, the strongest support comes from th.

Does Viagra reduce mortality in pulmonary fibrosis?
https://www.mdedge.com/chestphysician/article/254988/pulmonology/does-viagra-reduce-mortality-pulmonary-fibrosis
Pam Harrison, MDedge News

May 26th, 2022 - Sildenafil (Viagra, Pfizer), a phosphodieterase-5 (PDE-5) inhibitor and a pulmonary-selective vasodilator, may reduce mortality in patients with idiopathic pulmonary fibrosis (IPF), compared with placebo or standard of care but it does not reduce.

see more →

Patient Education  5 results see all →